Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2005
06/21/2005CA2213339C Method of treating adenosine depletion
06/17/2005CA2479432A1 Thiazole derivatives
06/16/2005WO2005054432A2 Gene transfer for regulating smooth muscle tone
06/16/2005WO2005054213A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
06/16/2005WO2005053387A1 Non-human mammalian and non-mammalian animal models of age-related memory impairment
06/16/2005WO2005020976A3 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
06/16/2005WO2005018532A3 Purine receptor binding compounds
06/16/2005WO2004099782A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
06/16/2005WO2004048565A9 Apoptosis-associated protein and use thereof
06/16/2005WO1990000853A8 Method of treating neurological disorders
06/16/2005US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
06/16/2005US20050132426 Using nuclear transplantation to generate non-human embryo from transferred nucleus of neural stem cell; gene targeting; knockout mutants
06/16/2005US20050131337 Analgesic drug delivery; skin discolroation inhibition
06/16/2005US20050131237 Indole derivatives
06/16/2005US20050131236 Central nervous ystem disorders; neurodegenerative disorders; muscle contraction; endocrine diseases
06/16/2005US20050131071 Orodispersible pharmaceutical composition of agomelatine
06/16/2005US20050131051 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon
06/16/2005US20050131047 cardiovascular disorders
06/16/2005US20050131044 Small molecule inhibitors of necrosis
06/16/2005US20050131043 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
06/16/2005US20050131040 Reacting losartan and poltassium compound in presence of water and aprotic solvent; salt formation
06/16/2005US20050131035 Medicaments
06/16/2005US20050131032 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
06/16/2005US20050131021 Phenoxy piperidines for treating diseases such as schizophrenia and depression
06/16/2005US20050131020 N-type calcium channel antagonists for the treatment of pain
06/16/2005US20050131005 4-azasteroid derivatives as androgen receptor modulators
06/16/2005US20050131003 Heterocyclic compounds
06/16/2005US20050130998 Central nervous ystem diorders; Alzheimer's disease ; anticancer agents
06/16/2005US20050130981 Compounds
06/16/2005US20050130979 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders
06/16/2005US20050130978 Novel crystal of quinoxalinedione derivative anhydride
06/16/2005US20050130967 3-Substituted-4-pyrimidone derivatives
06/16/2005US20050130966 Sodium channel modulators
06/16/2005US20050130965 Inhibitors of p38 kinase
06/16/2005US20050130964 e.g 8-oxa-1-thia-benzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester; rheumatoid arthritis
06/16/2005US20050130962 Seratonin receptor antagonist; central nervous system disorders; halo phenyl substituents
06/16/2005US20050130953 Pharmacological uses of azetidine derivatives
06/16/2005US20050130948 Therapeutic methods and uses of sapogenins and their derivatives
06/16/2005US20050130942 (E)-2,4,6-trimethoxystyryl-4-methoxy-3-aminobenzylsulfone for example; cancer, tumors, multiple sclerosis, Pagets disease; antibody conjugates; target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade
06/16/2005US20050130941 Methods of treating alzheimer's disease
06/16/2005US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
06/16/2005US20050130927 For treating neoplasm, hypoproliferation, hyperproliferation, degenerative and neurodegenerative diseases, ischaemia, immune system disorder, infectious disease, or metabolic dysfunction
06/16/2005US20050130907 N,N'-bis(halophenethyl)aminoalkylamide compounds of given formula as novel pain relievers for cancer or neuropathic pain, or use in cosmetic aftershave or after-sun product; works by inhibiting the vanilloid receptors and show a marginal activity on the NMDA receptor and the neuronal calcium channels
06/16/2005US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/16/2005US20050130902 Upregulate expression of a gene encoding an antioxidative anzyme, such as superoxide dismutase or catalase; neurodegenerative, cardiovascular, cerebral, disorders, trauma, injuries, burns, cancer
06/16/2005US20050130900 Sustained release drug formulations containing a carrier peptide
06/16/2005US20050130888 Use of metallothionein as an active ingredient in effecting and enhancing recovery of damaged neuronal tissue, particularly following physical trauma and damage thereto
06/16/2005US20050130881 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
06/16/2005US20050130304 Regulation of endogenous gene expression in cells using zinc finger proteins
06/16/2005US20050130286 For diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders
06/16/2005US20050130195 Functional molecule and process for producing the same
06/16/2005US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening
06/16/2005US20050129774 Mixture with surfactant and another drug; analgesics; antiinflammatory agents
06/16/2005US20050129739 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
06/16/2005US20050129737 Devices and methods for pain management
06/16/2005US20050129716 Therapeutic use of botulinum toxins types A and B
06/16/2005US20050129691 Using A beta antibody antagonist eg immunoglobulin; obsessive-compulsive disorder, panic disorder, panic attack, agoraphobia, post-traumatic stress disorder, social phobia, disruptive behavior disorder, and chronic fatigue syndrome
06/16/2005US20050129664 Remedy for dysmnesia
06/16/2005US20050129663 Cellular therapy; for promoting axonal regeneration in the CNS, wound healing and treatment of myocardial infarction and spinal cord injury
06/16/2005US20050129657 Interferon-alpha induced gene
06/16/2005US20050129621 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
06/16/2005DE60103627T2 SELBSTEMULGIERENDES ARZNEISTOFFVERABREICHUNGSSYSTEM, wobei das Fettmittel optional ist A self-DRUG ADMINISTRATION SYSTEM, wherein the fat means is optional
06/16/2005DE10352449A1 Product for preventing or treating Alzheimer's disease comprises sphingomyelin and/or an activator of endogenous sphingomyelin synthesis and/or an inhibitor of endogenous sphingomyelin degradation
06/16/2005CA2549119A1 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions
06/16/2005CA2547887A1 Protein modifier production inhibitor
06/16/2005CA2547780A1 Antisense compounds targeted to connexins and methods of use thereof
06/16/2005CA2547759A1 Vanadium compounds as inhibitors of phosphatases
06/16/2005CA2547652A1 Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
06/16/2005CA2547651A1 Anti-inflammatory agents
06/16/2005CA2547639A1 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
06/16/2005CA2545992A1 Pyrazolyl and imidazolyl pyrimidines
06/16/2005CA2545543A1 Novel use of peptide compounds for treating central neuropathic pain
06/15/2005EP1541580A1 Sulfotransferase inhibitors
06/15/2005EP1541576A1 Furoisoquinoline derivative and use thereof
06/15/2005EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541563A1 Ccr4 antagonist and medicinal use thereof
06/15/2005EP1541197A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
06/15/2005EP1541176A1 Adhesive patch
06/15/2005EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
06/15/2005EP1541156A1 Inhalation medicament comprising argon and its use for the treatment of neurotoxicity
06/15/2005EP1541154A1 Medicinal composition for drug-induced neuropathy
06/15/2005EP1541149A1 Phosphodiesterase inhibitor
06/15/2005EP1541147A1 Improved delivery of multiple doses of a methylphenidate drug
06/15/2005EP1541138A1 Novel use of peptide compounds for treating status epilepticus or related conditions
06/15/2005EP1541125A1 Spreadable compositions for topical use, a process of making same and uses thereof
06/15/2005EP1540332A1 Methods of screening compounds for grk6 modulating activity
06/15/2005EP1539976A2 Method for producing biodegradable, functionalised polymer particles, and use of the same as medicament carriers
06/15/2005EP1539933A2 Methods of organ regeneration
06/15/2005EP1539802A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
06/15/2005EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors
06/15/2005EP1539767A2 Opiate analogs selective for the delta-opioid receptor
06/15/2005EP1539766A1 Calcitonin gene related peptide receptor antagonists
06/15/2005EP1539765A1 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
06/15/2005EP1539764A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539760A2 Azapurine derivatives
06/15/2005EP1539751A1 Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
06/15/2005EP1539749A2 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
1 ... 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 ... 1833